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ABSTRACT
We report an optimized synthesis of all canonical
20-O-TOM protected ribonucleoside phosphoramid-
ites and solid supports containing [13C5]-labeled
ribose moieties, their sequence-specific introduc-
tion into very short RNA sequences and their use for
the structure determination of two protein–RNA
complexes. These specifically labeled sequences
facilitate RNA resonance assignments and are
essential to assign a high number of sugar–sugar
and intermolecular NOEs, which ultimately improve
the precision and accuracy of the resulting struc-
tures. This labeling strategy is particularly useful for
the study of protein–RNA complexes with single-
stranded RNA in solution, which is rapidly an
increasingly relevant research area in biology.
INTRODUCTION
Unambiguous RNA resonance assignments and identification
of a sufficient number of intermolecular NOEs is often one of
the limiting factors preventing a rapid structure determination
of protein–RNA complexes with NMR spectroscopy (1,2).
Reasons for this limitation originate from the severe reson-
ance overlap that is present in RNA compared to proteins
especially within the sugar protons of the RNA that all reson-
ate within one p.p.m. except for the anomeric proton (3). To
overcome this problem, methods based on in vitro transcrip-
tion have been developed to isotopically label RNA with 13C
and 15N and to facilitate RNA resonance assignments and the
structure determination of RNAs and protein–RNA com-
plexes (4,5). Although, they have been successfully used to
study RNA of 20 nt or more in size in complex with proteins
(1,2), labeling methods to produce short RNA oligonuc-
leotides (2 to 10 in size) by in vitro transcription failed (6).
Yet, isotopic labeling of short RNAs would be very useful
to confidently assign the resonances of short RNAs in
complex with proteins and to improve the precision of the
resulting structures. Recently, three structures of proteins in
complex with short single-stranded RNAs have been determ-
ined with NMR spectroscopy, namely SF1 (7), TIS11d (6) and
the Argonaute PAZ domain (8). All three were studied with
unlabeled RNA making the resonance assignment of the
RNA in complex very challenging, especially in the presence
of an RNA with low sequence complexity like 50-
UUAUUUAUU-30 used in the TIS11d–RNA complex (6).
Here, we report the synthesis of several short RNA
sequences (4 to 7 nt) with [13C5]-labeled riboses at specific
positions and their application for the resonance assignments
and for the structure determination of two alternative-splicing
factors, polypyrimidine tract binding protein (PTB) and fem-
inizing locus on X (Fox-1), in complex with RNA. For this
purpose, we evaluated and optimized the various reported
synthetic methods (9–12) for the preparation of [13C5]-
ribonucleosides from [13C6]-D-glucose. These intermediates
were then converted into the corresponding 20-O-[(triisopro-
pylsilyl)oxy]methyl (¼ 20-O-TOM) protected ribonucleoside
phosphoramidites, which allows an efficient preparation of
RNA sequences under DNA coupling conditions (13,14).
Chemical synthesis allows efficient 13C-labeling of very
short RNAs and the possibility to introduce isotope-labeling
at any position in the sequence, providing a fundamental
advantage over isotope-labeling by in vitro transcription
(1,2). Using chemically synthesized 13C-labeled RNA, RNA
resonance assignment was greatly facilitated as several ambi-
guities could be resolved. Also a very high number of inter-
molecular and intramolecular sugar–sugar NOE cross-peaks
could be assigned permitting to obtain structures of very
high precision (15,16).
MATERIALS AND METHODS
General
Reagents and solvents (highest purity) from various suppliers,
used without further purification, unless otherwise stated.
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[1,2,3,4,5,6–13C6] glucose (
13C > 99%) from Spectra Stable
Isotopes (Columbia, MD). Work up implies distribution of
the reaction mixture between CH2Cl2 and saturated aqueous
NaHCO3 solution, drying of the organic layer (MgSO4),
and evaporation. TLC: pre-coated silica gel plates from
Merck, stained by dipping into a solution of anisaldehyde
(10 ml), H2SO4 (10 ml) and AcOH (2 ml) in EtOH (180 ml)
and subsequent heating with a heat-gun. Column chromato-
graphy (CC): silica gel 60 (230–400 mesh) from Fluka.
NMR (Bruker): chemical shift d in p.p.m., relative to external
standards (1H- and 13C: Me4Si,
31P: 85% aqueous H3PO4);
coupling constants J in Hz; multiplicities (13C) according
to DEPT-spectra. ESI-MS (positive mode): SSQ 710
(Finnegan), measurements in MeCN/H2O/AcOH 50:50:1;
MALDI-MS (positive mode): Axima CFR Plus (Kratos/
Shimadzu), matrix: 2,4,6-trihydroxyacetophenone (50 mg/ml),
di-ammonium hydrogen citrate (15 mg/ml) in H2O/MeCN
(1:1); relative intensity in % as indicated in brackets.
[1,2,3,4,5–13C5]-1,2-Di-O-acetyl-3,5-di-O-benzoyl-a,
b-D-ribofuranose (1)
Prepared essentially according to Saito et al. (17), for experi-
mental details see Supplementary Data.
[10,20,30,40,50–13C5]-6-Allyloxy-2-amino-N
2-isobutyryl-
50-O-(4,40-dimethoxytrityl)purine (3)
A suspension of 1 (3.20 g, 7.15 mmol) and 2-amino-6-chloro-
N2-isobutyrylpurine (2.06 g, 8.61 mmol) in (CH2Cl)2 (28 ml)
was treated with N,O-bis(trimethylsilyl)acetamide (2.63 ml,
10.77 mmol). After 15 min at 65C, TMS-OTf (4.53 ml,
25.13 mmol) was added and the mixture was stirred 30 min
at 65C. After usual work up, the intermediate 2 was dis-
solved in allyl alcohol (23 ml), treated with DABCO (1.21 g,
10.77 mmol) and DBU (1.61 ml, 10.77 mmol). After 1 h at
20, the reaction mixture was diluted with CH2Cl2 (150 ml),
extracted with 10% citric acid (200 ml), washed with satur-
ated NaHCO3 (150 ml) and dried over MgSO4. After evap-
oration, the residue was dissolved in THF/MeOH 5:4
(180 ml), cooled to 0 and treated with 2N NaOH (18 ml).
After 10 min at 0, ion exchange resin IR 120 (H+ form, 30 ml)
was added until the pH 7. The resin was filtered off and
washed with THF/MeOH 5:4. The solvents were evaporated;
the residue was co-evaporated with pyridine and dried under
vacuum (0.01 mbar). The residue was dissolved in pyridine
(30 ml) and treated with (MeO)2TrCl (2.9 g, 8.62 mmol).
After 1 h at 20, the reaction mixture was subjected to usual
work up. CC [75 g SiO2, CH2Cl2 (+2% NEt3) ! CH2Cl2/
MeOH 97:3 (+2% NEt3)] gave 3 (3.26 g, 65%) as yellow
foam. TLC (CH2Cl2/MeOH 9:1) Rf 0.58.
1H-NMR (13C
decoupled, 400 MHz, CDCl3): 1.32, 1.34 (2d, J ¼ 6.6,
Me2CHCO); 2.62 (heptett, J ¼ 6.8, Me2CHCO); 3.20 [d, J ¼
9.7, H–C(50)]; 3.37 [d, J ¼ 10.2, H0–C(50)]; 3.45 (br. s, HO);
3.77 (s, 2 MeO); 3.79 (br. s, HO); 4.42 [m, H–C(40)]; 4.50 [m,
H–C(30)]; 4.95 [s, H–C(20)]; 5.09 (d, J ¼ 5.4, OCH2CH¼CH2);
5.33 (dd, J¼ 10.4, 0.8, 1H, OCH2CH¼CH2); 5.48 (dd, J¼ 17.3,
0.8 1H OCH2CH¼CH2); 5.94 [d, J ¼ 5.2, H–C(10)]; 6.15,
(m, OCH2CH¼CH2); 6.68–6.75 (m, 4 arom. H); 7.09–7.40 (m,
9 arom. H); 7.46 [br. s, HN-C(2)]; 8.13 [s, H–C(8)]. 13C-NMR
(100 MHz, CDCl3): 19.4 (Me2CHCO); 37.2 (Me2CHCO); 55.2
(MeO); 64.2 [d, J¼ 42, C(50)]; 68.6 (OCH2CH¼CH2); 72.2 [dd,
J¼ 38, C(40)]; 77.1 [dd, J¼ 38, C(20)]; 87.4 [dd, J¼ 41, C(30)];
88.8 (arom. C); 92.6 [d, J¼ 39, C(10)]; 113.5 (arom. CH); 119.2
(OCH2CH¼CH2); 127.2, 128.2, 130.3, 130.4, 132.4 (5 arom.
CH); 135.8, 135.9 (2 arom. C), 140.4 [C(8)]; 144.7 (arom. C);
151.5 [C(6)]; 152.0 [C(2)]; 158.88 (arom. C), 161.2 (arom. C);
175.7 (Me2CHCO). ESI-MS: 701.31 (100, [M + H]+).
[10,20,30,40,50–13C5]-50-O-(4,40-Dimethoxytrityl)-
N2-(isobutyryl)guanosine (4)
A solution of 3 (3.44 g, 4.91 mmol) in CH2Cl2 (20 ml) was
treated with Et2NH (1.28 ml, 12.3 mmol), PPh3 (296 mg,
1.13 mmol) and Pd(PPh3)4 (30 mg, 0.03 mmol). After 30 min
at 20, SiO2 (9 g) was added and the solvent was evaporated.
The residue was purified by CC [10 g SiO2, CH2Cl2 (+2%
Et3N) ! CH2Cl2/MeOH 95:5 (+2% Et3N)]: 4 (2.90 g, 89%).
TLC (CH2Cl2/MeOH 9:1) Rf 0.47.
1H-NMR (13C decoupled,
400 MHz, CDCl3): 0.81, 1.00 (2d, J  6, Me2CHCO);
2.83 (br. q, J  7, Me2CHCO); 3.19 [m, H–C(50)]; 3.40 (br.
d, J ¼ 6.7, HO); 3.47 [m, H0–C(50)]; 3.75, 3.76 (2s, 2 MeO);
4.31 [m, H–C(40)]; 4.55 [m, H–C(30)]; 5.14 [s, H–C(20)]; 5.87
[d, J ¼ 5.2, H–C(10)]; 6.75–6.85 (m, 4 arom. H); 7.10–7.50
(m, 9 arom. H); 7.78 [s, H–C(8)]; 9.46 [br. s, HN-C(2)];
12.16 [br. s, H-N(1)]. 13C-NMR (100 MHz, CDCl3): 18.5,
18.7 (Me2CHCO); 35.8 (Me2CHCO); 55.2 (MeO); 63.7
[d, J ¼ 43, C(50)]; [71.5 (t, J ¼ 38), 73.9 (t, J ¼ 39), 85.1
(t, J ¼ 41): C(20), C(30), C(40)]; 90.0 [d, J ¼ 41, C(10)]; 113.2
(arom. CH); 121.0 [C(50)]; 126.9, 127.9, 128.1, 129.9, 130.0
(5 arom. CH); 135.7, 136.1 (2 arom. C); 138.9 [C(8)]; 144.7
(arom. C); 147.4 [C(4)]; 148.2 [C(2)]; 155.8 [C(6)];
158.6 (arom. C); 179.7 (Me2CHCO). ESI-MS: 661.36 (100,
[M + H]+).
[10,20,30,40,50–13C5]-N
6-Benzoyl-50-O-(4,40-
dimethoxytrityl)adenosine (5)
A suspension of 1 (3.20 g, 7.15 mmol) and N6-benzoyladen-
ine (2.05 g, 8.59 mmol) in (CH2Cl)2 (28 ml) was treated with
N,O-bis(trimethylsilyl)acetamide (2.62 ml, 10.74 mmol). The
mixture was stirred at 65C for 15 min, treated with SnCl4
(2.9 ml, 25.06 mmol) and stirred 30 min at 65C. After
usual work up, the residue was dissolved in THF–MeOH
5:4 (250 ml), cooled to 0 and treated with 2N NaOH
(25 ml). After 40 min at 0, ion exchange resin IR 120
(H+ form, 30 ml) was added until the pH 7. The resin was fil-
tered off and washed with THF–MeOH 5:4. The solvents
were evaporated; the residue was co-evaporated with pyridine
and dried under vacuum (0.01 mbar). The residue was dis-
solved in pyridine (30 ml) and treated with (MeO)2TrCl
(3.20 g, 9.5 mmol). After 1 h at 20, the reaction mixture
was subjected to usual work up. CC [75 g SiO2, CH2Cl2
(+2% NEt3) ! CH2Cl2/MeOH 24:1 (+2% NEt3)] gave 5
(3.79 g, 78%) as yellow foam. TLC (CH2Cl2/MeOH 9:1) Rf
0.44. 1H-NMR (13C decoupled, 400 MHz, CDCl3): 2.03
(br. s, HO); 3.35 [d, J ¼ 9.7, H–C(50)]; 3.48 [d, J ¼ 9.7,
H0–C(50)]; 3.77 (s, 2 MeO); 4.42 [m, H–C(40)]; 4.50
[m, H–C(30)]; 4.93 [m, H–C(20)]; 5.83 (br. s, HO);
6.10 [d, J ¼ 4.2, H–C(10)]; 6.75–6.79 (m, 4 arom. H);
7.16–7.38 (m, 9 arom. H); 7.49–7.69 (m, 3 arom. H);
8.02 (d, J ¼ 7.3, 2 arom. H); 8.25 [s, H–C(8)]; 8.67
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[s, H–C(2)]; 9.19 [br. s, HN-C(6)]. 13C-NMR (100 MHz,
CDCl3): 55.2 (MeO); 63.5 [d, J ¼ 43, C(50)]; [72.2 (t, J ¼
38), 75.4 (dd, J ¼ 37, 40), 85.6 (dd, J ¼ 39, 43): C(20),
C(30), C(40)]; 86.5 (arom. C); 90.0 [d, J ¼ 41, C(10)]; 113.1
(arom. CH); 122.9 [C(5)]; 126.9, 127.7, 127.8, 127.9,
128.0, 128.3, 128.9, 129.1, 129.9 (9 arom. CH); 132.9,
135.4, 135.5 (3 arom. C); 141.6 [C(8)]; 144.4 (arom. C);
149.4 [C(6)]; 151.0 [C(4)]; 152.2 [C(2)]; 158.5 (arom. C);
164.7 (PhCO). ESI-MS: 679.39 (100, [M + H]+).
[10,20,30,40,50–13C5]-50-O-(4,40-Dimethoxytrityl)uridine (6)
A suspension of 1 (1.70 g, 3.80 mmol) and uracil (0.52 g,
4.64 mmol) in MeCN (19 ml) was treated with N,O-bis(tri-
methylsilyl)acetamide (2.80 ml, 11.1 mmol) and stirred at
60C for 30 min. Then, TMS-OTf (2.44 ml, 13.3 mmol)
was added and the mixture was stirred 30 min at 60C.
After usual work up, the resulting intermediate was dissolved
in 8 M MeNH2 in EtOH (19 ml) and stirred overnight at 20
.
The solvent was evaporated; the residue was co-evaporated
with pyridine and dried overnight under vacuum (0.01
mbar). The solid was dissolved in pyridine (19 ml) and trea-
ted with (MeO)2TrCl (1.80 g, 5.32 mmol). After 1 h at 20
,
the reaction mixture was subjected to usual work up. CC
(40 g SiO2, CH2Cl2 (+2% Et3N) ! CH2Cl2/MeOH 19:1
(+2% Et3N)) gave 7 (1.49 g, 71%) as pink foam. TLC
(CH2Cl2/MeOH 9:1) Rf 0.50.
1H-NMR (13C decoupled,
400 MHz, CDCl3): 3.48 [d, J ¼ 10.4, H–C(50)]; 3.55 [d, J ¼
10.5, H–C(50)]; 3.79 (s, 2 MeO); 4.19 [d, J  4.1, H–C(40)];
4.34 [m, H–C(20)]; 4.43 [m, H–C(30)]; 5.38 [d, J ¼ 8.1,
H–C(5)]; 5.92 [br. s, H–C(10)]; 6.83–6.88 (m, 4 arom. H);
7.22–7.41 (m, 9 arom. H); 8.00 [d, J ¼ 8.1, H–C(6)].
13C-NMR (100 MHz, CDCl3): 55.2 (MeO); 61.8 [d, J ¼
43, C(50)]; [69.6 (t, J ¼ 69), 75.4 (dd, J ¼ 37, 41), 83.7
(dd, J ¼ 43, 39): C(20), C(30), C(40)]; 86.9 (arom. C); 90.4
(d, J ¼ 42), [C(10)]; 102.2 [C(5)]; 113.2 (arom. CH); 127.1,
128.0, 128.1, 130.0, 130.1 (5 arom. CH); 135.1, 135.3
(2 arom. C); 140.4 [C(6)]; 144.3 (arom. C); 151.2 [C(2)];
158.6 (arom. C); 163.9 [C(4)]. MALDI-MS: 574.5 (100,
[M + Na]+).
[10,20,30,40,50–13C5]-50-O-(4,40-Dimethoxytrityl)-
N2-isobutyryl-20-O-{[(triisopropylsilyl)oxy]methyl}
guanosine (7), [10,20,30,40,50–13C5]-N
6-benzoyl-50-O-
(4,40-dimethoxytrityl)-20-O-{[(triisopropylsilyl)oxy]
methyl}adenosine (8) and [10,20,30,40,50–13C5]-50-O-
(4,40-dimethoxytrityl)-20-O-{[(triisopropylsilyl)
oxy]methyl}uridine (9)
Prepared essentially according to Pitsch et al. (14), for experi-
mental details see Supplementary Data.
[10,20,30,40,50–13C5]-N
4-Acetyl-50-O-(4,40-
dimethoxytrityl)-20-O-{[(triisopropylsilyl)oxy]methyl}
cytidine (10)
Prepared according to Wenter et al. (18), for experimental
details see Supplementary Data.
[10,20,30,40,50–13C5]-N
2-isobutyryl-50-O-(4,40-
dimethoxytrityl)-20-O-{[(triisopropylsilyl)
oxy]methyl}guanosine 30-(2-cyanoethyl
diisopropylphosphoramidite) (11),
[10,20,30,40,50–13C5]-N
6-Benzoyl-50-O-(4,40-
dimethoxytrityl)-20-O-{[(triisopropylsilyl)
oxy]methyl} adenosine 30-(2-cyanoethyl
diisopropylphosphoramidite) (12), [10,20,30,40,50–13C5]-
50-O-(4,40-Dimethoxytrityl)-20-O-{[(triisopropylsilyl)
oxy]methyl}uridine 30-(2-cyanoethyl
diisopropylphosphoramidite) (13) and [10,20,30,40,
50–13C5]-N
4-cetyl-50-O-(4,40-dimethoxytrityl)-20-O
{[(triisopropylsilyl)oxy]methyl}cytidine 30-(2-
cyanoethyl diisopropylphosphoramidite) (14)
Prepared according to Pitsch et al. (14), for experimental
details see Supplementary Data.
Solid supports
Prepared according to Pitsch et al. (14), for structures and
experimental details see Supplementary Data.
Assembly and deprotection of RNA sequences S1–S6
The RNA sequences S1–S6 were assembled from the 13C5-
labeled phosphoramidites 11–14 and the corrresponding 20-O-
TOM protected, unlabeled phosphoramidites on a Gene
Assembler Plus (Pharmacia) in a 1 mmol scale according to
(14). After the assembly, the solid supports were treated
with a 1:1 mixture of 12 M MeNH2 in H2O/8 M MeNH2 in
EtOH (1 ml) for 3 h at 35. By centrifugation, the supernatant
solution was separated from the solid support and evaporated,
and the residue was dissolved in 1 M Bu4NF·3 H2O solution
in THF (1 ml). After 14 h at 20, 1 M Tris–HCl buffer
(pH 7.4, 1 ml) was added and the solution concentrated to
half its volume.
Desalting and purification of RNA sequences
r([13C
05]Cp[13C
05]Up[13C
05]Cp[13C
05]U) (S1),
r(Cp[13C
05]UpCp[13C
05]U) (S2),
r([13C
05]Up[13C
05]Cp[13C
05]Up[13C
05]Cp[13C
05]U) (S3) and
r([13C
05]UpCp[13C
05]UpCp[13C
05]U) (S4)
The remaining solution from above (1 ml) was applied on a
NAP-10 cartridge (Pharmacia) and eluted with H2O. Two
fractions were collected: fraction 1 (1.5 ml) and fraction 2
(1 ml). Fraction 2 was again applied to a NAP-10 cartridge
and eluted with H2O. The first 1.5 ml solution was combined
with fraction 1 and purified by anion exchange–high-
performance liquid chromatography (HPLC): Pharmacia
Source 15Q column (4.5 · 100 mm), flow 2 ml/min, eluent
A: 50 mM NEt3·H2CO3, eluent B: 1 M NEt3·H2CO3, detec-
tion at 260 nm, elution at 20, gradient 0–45% B in 40 min,
1 injection. The fractions containing pure product were
pooled and subjected to lyophilization. In order to completely
remove the remaining NEt3·H2CO3, 0.5 ml H2O were added
to the residue, followed by lyophilization (this procedure was
carried out twice). The residue was dissolved in H2O (0.5 ml),
treated with NaHCO3 (5 mg) and lyophilized twice. Final
desalting on a NAP-10 cartridge was performed as described
above, resulting in pure RNA sequences S1–S4 as Na+ salts.
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Their amount was determined spectrophotometrically. S1
(2 syntheses, 0.68 mg, 0.58 mmol, 29% yield), MALDI-MS
(negative mode): 1182 a.m.u. [M+H]+; S2 (2 syntheses,
0.66 mg, 0.56 mmol, 28% yield), MALDI-MS (negative
mode): 1172 a.m.u. [M+H]+; S3 (2 syntheses, 1.27 mg,
0.85 mmol, 43% yield), MALDI-MS (negative mode): 1493
a.m.u. [M+H]+; S4 (2 syntheses, 1.26 mg, 0.85 mmol, 43%
yield), MALDI-MS (negative mode): 1483 a.m.u. [M+H]+.
Desalting and purification of RNA sequences
r([13C
05]UpGp[13C
05]CpAp[13C
05]UpGpU) (S5) and
r(Up[13C
05]GpCp[13C
05]ApUp[13C
05]Gp[13C
05]U) (S6)
The remaining solution from above (1 ml) was applied on a
NAP-10 cartridge (Pharmacia) and eluted with H2O. The first
1.5 ml solution was purified by anion exchange–HPLC: Phar-
macia Source 15Q column (4.5 · 100 mm), flow 2 ml/min,
eluent A: 12.5 mM Tris–HCl (pH 7.5); eluent B: 12.5 mM
Tris–HCl (pH 7.5), 1 M NaCl; detection at 260 nm, eluent
at r.t., gradient 0–50% B in 45 min, two injections. Fractions
containing pure product were treated with 1 M aqueous
Et3N·H2CO3 to a final 0.1 M concentration and applied to a
Sepak cartridge [Waters, conditioned by washing with
MeCN (10 ml) and 0.1 M aqueous Et3N·H2CO3 (10 ml)].
The cartridge was washed with 20 mM Et3N·H2CO3 (10
ml) and the RNA sequences were eluted with MeCN/H2O
1:1 (4 ml). In order to completely remove the remaining
NEt3·H2CO3, 0.5 ml H2O were added to the residue, followed
by lyophilization (this procedure was carried out twice). The
residue was dissolved in H2O (0.5 ml), treated with NaHCO3
(10 mg) and lyophilized twice. Final desalting on a NAP-10
cartridge was performed as described above, resulting in pure
RNA sequences S5 and S6 as Na+ salts. Their amount was
determined spectrophotometrically. S5 (4 syntheses, 4.50 mg,
2.05 mmol, 51% yield), MALDI-MS (negative mode):
2197 a.m.u. [M+H]+; S6 (4 syntheses, 3.43 mg, 1.56 mmol,
39% yield), MALDI-MS (negative mode): 2201 a.m.u.
[M+H]+.
Preparation of protein, NMR-measurements, RNA
resonance assignments and structure calculation
The preparation of PTB and Fox-1 proteins and the related
NMR-measurements are reported in Oberstrass et al. (16)
and Auweter et al. (15), respectively. The structure calcula-
tion of the Fox-1 complex with the reduced set of NOE
O
BzO OAc
BzO
[13C6]-D-glucose
OAc
1 (40%)
O
R2O OR1
DMTO BASE
(N2-Ibu)G
(N6-Bz)A
U
(N4-Ac)C
R1 = R2 = H R1 = TOM, R2 = H R1 = TOM, R2 = P(OCE)(NiPr2)
7
8
9
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4 (89%)
5 (78%)
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O
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N
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N
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N
H
O
O
HO OH
DMTO
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N
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O
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(e)
(f) (h)
(g)
Scheme 1. Preparation of the [13C5]-ribose-labeled 2
0-O-TOM protected ribonucleoside phosphoramidites 11–14. Abbreviations: Ac ¼ acetyl, Bz ¼ benzoyl,
Ibu ¼ isobutyryl, CE ¼ cyanoethyl, DMT ¼ (4,40-dimethoxy)trityl, TOM ¼ (triisopropylsilyl)oxymethyl. Reagents and conditions: (a) Adapted from Saito et al.
(17), detailed procedure in Supplementary Data: 1. FeCl3, MgSO4, acetone, 20
; 2. pyridinium dichromate, Ac2O, CH2Cl2, reflux; 3. H5IO6, THF, 20; 4. NaBH4,
THF/EtOH 1:1, 20; 5. BzCl, pyridine, 20; 6. Ac2O, AcOH, H2SO4, 20. (b) 6-Chloro-N
2-isobutyrylpurine-2-amine, N,O-bis(trimethylsilyl)acetamide (BSA),
Me3SiOTf, 1,2-dichloroethane, 65
. (c) 1. Allyl alcohol, DABCO, DBU, 20; 2. NaOH, THF/MeOH/H2O, 0; 3. DMT-Cl, pyridine, 20. (d) Pd(Ph3P)4, HNEt2,
PPh3, CH2Cl2, 20
. (e) Synthesis of 5: 1. N6-benzoyladenine, BSA, SnCl4, 1,2-dichloroethane, 65; 2. NaOH, THF/MeOH/H2O, 0; 3. DMT-Cl, pyridine, 20;
synthesis of 6: 1. uracil, BSA, Me3SiOTf, MeCN, 60
; 2. MeNH2, EtOH, 20; 3. DMT-Cl, pyridine, 20. (f) Bu2SnCl2,
iPr2NEt, TOM-Cl, 1,2-dichloroethane, 80

according to (14). (g) 1. Ac2O, DMAP, pyridine 25
; 2. 4-chlorophenyl phosphorodichloridate, 1H-1,2,4-triazole, iPr2NEt, MeCN, 4 ! 20; 3. aqueous NH3,
dioxane/MeCN, 20; 4. NaOH, THF/MeOH/H2O, 4 5. Ac2O, DMF, 20, according to (18). (h) 2-Cyanoethyldiisopropylphosphoramidochloridite,
iPr2NEt,
CH2Cl2, 20
, according to (14).
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distance constraints from the unlabeled RNA sequence was
performed in a restrained simulated annealing run using
AMBER 7.0, following the same protocol that was employed
for the structure calculation of the Fox-1 complex with the
entire set of constraints; see (15).
RESULTS AND DISCUSSION
Preparation of the 13C5-ribose-labeled ribonucleoside
phosphoramidites
For the preparation of the four canonical, 13C5-ribose-labeled
20-O-TOM protected ribonucleoside phosphoramidites and
solid supports, we adapted and optimized existing reaction
conditions with the purpose of minimizing the number of
time-consuming purification steps (Scheme 1). The four-
step synthesis of the protected 13C5-ribose derivative 1 from
13C6-labeled D-glucose (40% yield) was carried out essen-
tially according to Saito et al. (17) and is described in the
Supplementary Data. The protected adenosine and uridine
derivatives 5 and 6 were obtained by nucleosidation of 1
with N6-benzoyladenosine (! 5) and uracil (! 6), respect-
ively, under optimized Vorbru¨ggen conditions, followed by
partial deacylation and dimethoxytritylation. The guanosine
derivative 6 was prepared according to a modified method
originally described for the synthesis of the corresponding
ribopyranosylguanosine phosphoramidite by Pitsch et al.
(19). In the presence of Me3SiOTf and in 1,2-dichloroethane,
1 reacted smoothly and completely regioselectively with
in situ trimethylsilylated N2-isobutyryl-6-chlor-2-aminopurine
to the purine derivative 2. Without purification, it was
treated with 1,4-diazabicyclo[2,2,2]octane (DABCO) and
1,8-diazabicyclo[5,4,0]undec-7-ene (DBU) in allyl alcohol,
resulting in the corresponding O6-allyl derivative which
was partially deacylated with NaOH in THF/MeOH/H2O
and then dimethoxytritylated with (MeO)2TrCl in pyridine
(! 3, 65% based on 1). Cleavage of the O6-allyl group
was achieved by treating the intermediate 3 with Et2NH in
the presence of [Pd(PPh3)4], resulting in formation of the
guanosine derivative 4 (89% yield).
The introduction of the 20-O-TOM protecting group into
nucleosides 4, 5 and 6 was carried out according to our stand-
ard procedure (14), with Bu2SnCl2,
iPr2NEt and TOM-Cl in
1,2-dichloroethane at 80 (detailed procedure in Supplement-
ary Data). The product mixture was separated into the 20-O-
TOM protected products 7–9, the unreacted starting materi-
als, and the 30-O-TOM protected regioisomers. The latter
were deprotected with Et4NF in MeCN, the products were
combined with the unreacted starting materials and subjected
again to alkylation with TOM-Cl. By this procedure, the 20-
O-TOM protected nucleosides 7–9 were obtained in fair
yields of 42–50% (Scheme 1). From the 20-O-TOM protected
uridine 9, the corresponding cytidine derivative 10 was
obtained according to our published method (18), in a yield
of 65%. Under standard conditions, the four 20-O-TOM pro-
tected nucleosides 7–10 were converted with 2-cyanoethyl
diisopropylphosphoramidochloridite/iPr2NEt in CH2Cl2 into
their corresponding phosphoramidite building blocks
(Scheme 1). The solids supports were prepared according
to (14) by first synthesizing the 20-O-(nitrophenylheptane)dio-
ates from the 30-O-tom nucleosides of adenosine, uridine and
cytosine and the 30-O-(nitrophenylheptane)dioate from the
20-O-TOM guanosine derivative. Then these activated esters
were immobilized on 500 s (aminoalkyl)-functionalized con-
trolled pore glass (CPG) with loadings from 25 to 35 mmol/g
(a detailed description for the preparation of phosphoramid-
ites 7–14 and the corresponding solid supports is given in
the Supplementary Data).
Chemical synthesis of the short 13C-labeled RNA
oligonucleotides
The short and partially labeled RNA sequences S1–S6
(Table 1) were assembled in 1 mM batches from conventional
20-O-TOM protected ribonucleoside phosphoramidites and
solid supports, and the corresponding 13C-labeled building
blocks 11–14, respectively, on an oligonucleotide synthesizer
according to our standard protocols (14). The isolation and
purification protocols of the shortest 4 and 5mer oligonuc-
leotides S1–S4 had to be modified, because of the small
size and small number of negative charges present (for a
detailed procedure see Materials and Methods). Finally, all
RNA sequences were converted into their Na+ salts and char-
acterized by MALDI-MS (Table 1).
NMR study of the 13C5-sugar labeled UCUCU and
CUCU in complex with PTB
The oligo(CU) sequences S1–S4 (Supplementary Table) con-
taining 13C5-sugar labeled nucleotides at various positions
were used for structure determination of PTB in complex
with its target RNA sequence. We had to use these very
short tetramers and pentamers, because PTB RBD1, RBD2
and RBD4 recognize only 3 nt and RBD3 only 5 nt (16).
As illustrated in the 13C HSQC spectrum of S3 bound to
PTB RBD34 H134A, complete or partial 13C-labeling of
the sugar moieties of these short RNAs allows resolving the
Table 1. Preparation of selectively 13C-labeled RNA sequences
Synthesisa Purificationb and MALDI-MSc
Sequence Scale Yield Condition [M+H+]calc [M+H+]found
(mmol) (mmol) (%) (a.m.u.) (a.m.u.)
S1: 50-CUCU-30 2 0.58 29 A 1182 1182
S2: 50-CUCU-30 2 0.56 28 A 1172 1172
S3: 50-UCUCU-30 2 0.85 43 A 1493 1493
S4: 50-UCUCU-30 4 0.85 43 A 1483 1483
S6: 50-
UGCAUGU-30
4 2.05 51 B 2196 2197
S7: 50-
UGCAUGU-30
4 1.56 39 B 2202 2201
aPreparation and deprotection of RNA-sequences according to Pitsch et
al.(14); underlined letters in sequences indicate 13C5-ribose-labeled nucleo-
sides.
bPurification and isolation: condition A: 1. Desalting on size-exclusion car-
tridges according to a modified protocol, 2. anion exchange–HPLC with aq.
Et3N·H2CO3 gradients, 3. Removal of buffer by repeated lyophilization,
4. Transformation into Na+salt form by addition of NaHCO3, repeated lyophi-
lization and desalting on size-exclusion cartridges; condition B: 1. Desalting on
size-exclusion cartridges according to the standard protocol, 2. Anion
exchange–HPLC with NaCl gradients, 3. Removal of eluent on C18-RP car-
tridges according to a modified protocol, 4. Transformation into Na+-salt form
by addition of NaHCO3, repeated lyophilization and desalting on size-
exclusion cartridges.
cMatrix: 2,4,6-trihydroxyacetophenone, di-ammonium citrate.
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strong proton resonance overlap in the sugar region of the
RNA in complex with PTB (Figure 1A). The RNAs contain-
ing only labeled uracils (S2 and S4) were essential to confirm
the resonance assignments of the bound RNAs (Figure 1B)
and to unambiguously derive intermolecular NOEs between
the sugar moiety and the protein side chains. Isotope-labeling
of the RNAs was essential to this structure determination as
50 and 67% of the intermolecular NOEs involved RNA
sugar resonances in the complex with RBD3 and RBD4 of
PTB, respectively (16).
NMR study of the 13C5-sugar labeled UGCAUGU in
complex with Fox-1
The partially 13C-labeled RNA oligonucleotides S5 and S6
were used to determine the structure with Fox-1 (16). The
two RNAs were essential to unambiguously assign the
RNA resonances and to collect a high number of intra- and
intermolecular NOE-derived constraints for UGCAUGU in
complex with Fox-1. Without isotopically labeled RNA, the
resonance assignment of the 7 nt RNA in complex was diffi-
cult and not unambiguous. While the proton resonances
within each individual nucleoside could be linked using
2D NOESY and 2D TOCSY spectra, it was not possible to
unambiguously place each individually assigned nucleotide
spin-systems in the RNA sequence. In particular, we were
doubtful about which spin-systems were corresponding to U5
and U7. With the 2D 13C HSQC spectra of the partially
13C-labeled RNA S6 and S7 in complex with Fox-1, these
ambiguities could be solved, as S6 contains a 13C5-labeled
U5 and S7 a 13C5-labeled U7 (Figure 2A). Importantly, with
the particular labeling scheme present in S6 and S7, in which
13C5-labeled and unlabeled nucleotides are present in alterna-
tion, unusual internucleotide sugar–sugar NOEs could be
assigned using X-filter NOESY spectra (20) (Figure 2B). In
total, 39 internucleotide sugar–sugar NOEs were assigned,
which corresponds to 68% of the internucleotide constraints
and one-third (31%) of the intra-RNA constraints. Only five
of these internucleotide sugar–sugar NOEs could be assigned
using an unlabeled RNA, the remaining 34 could only be
resolved using labeled S6 and S7 due to ambiguity or reson-
ance overlap. Similarly, of the 149 intermolecular distance
constraints, which were used to calculate the Fox-1 complex
structure, 83 originate from the sugar protons of the RNA
and 57 of these could not have been assigned without the
help of the labeled oligonucleotides (15). A structure calcu-
lation without the distance constraints from the 13C-labels
resulted in a set of structures in which the RNA is signific-
antly less defined: the RMSD of the heavy atoms of the
RNA is 1.02 s as compared to 0.55 s in the case when
all NOE distance constraints were included (Figure 2C).
While each nucleotide is affected, the effect is strongest at
the 50 and 30 terminal ends of the RNA. In particular, nuc-
leotide U7 does not converge to one particular conformation
(Figure 2C). Furthermore, the relative orientation of protein
and RNA is less precise (Figure 2C). The complex structure
of Fox-1 using all constraints is extraordinarily well defined,
allowing a detailed analysis of the individual hydrogen
bond, van der Waals and electrostatic interactions at the
protein–RNA interface (15). In the structures obtained
with the reduced set of constraints, an equal level of preci-
sion cannot be reached. Especially the intermolecular con-
tacts to the RNA backbone are more heterogeneous. For
example, a salt bridge between lysine 156 and the phosphate
between G6 and U7 is observed in 28 of 30 structures
(Figure 2C, left). In contrast, this salt bridge is observed
in only 11 of the 30 structures obtained with the smaller
number of NOE distance constraints (Figure 2C, middle).
Hence, these NOEs were critical to determine with high pre-
cision the very unusual structure that the RNA adopts when
bound to the RBD of Fox-1.
CONCLUSION AND PERSPECTIVES
In conclusion, we present a short and efficient synthetic
access to 20-O-TOM protected ribonucleoside phosphoramid-
ites containing 13C-labeled sugar moieties. The site-specific
Figure 1. (A) 13C HSQC spectra of UCUCU (S3) bound to PTB34 H134A (red). (B) 13C HSQC spectra of UCUCU (S4) bound to PTB34 H134A. In S4, only the
uridines are 13C-labeled. The assignment is indicated and in spectrum (A), a cross indicates the position of the cross-peaks from cytidine resonances.
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Figure 2. (A) 13C HSQC spectra of 1mM Fox-1 in complex with S6 (red) or S7 (blue). (B) Left: section of a 2D NOESY spectrum of1 mM Fox-1 (unlabeled)
in complex with UGCAUGU (unlabeled) showing the extreme overlap in the RNA sugar resonances. Middle left: the same section of a w1, w2-filtered 2D
NOESY spectrum of 1 mM Fox-1 (uniformly 13C-labeled) in complex with UGCAUGU (unlabeled). In this spectrum, NOE cross-peaks arise only from intra-
RNA correlations; overlap is reduced but assignments remain ambiguous. Middle right: the same section of a w1-filtered, w2-edited 2D NOESY spectrum of
1 mM Fox-1 (unlabeled) in complex with S6. NOE cross-peaks arise from correlations of protons attached to 13C (w2) with protons attached to 12C (w1). Right:
the same section of a w1-filtered, w2-edited 2D NOESY spectrum of 1 mM Fox-1 (unlabeled) in complex with S7. NOE cross-peaks arise from correlations of
protons attached to 13C (w2) with protons attached to 12C (w1). Underlined NOE assignments are displayed in the structure of the complex with green dashed
lines in (C). Overlap and ambiguity are significantly reduced in the spectra with S6 and S7 and many internucleotide cross-peaks can be assigned due to the
alternating labeling scheme. (C) Left: overlay of the 30 final structures of Fox-1 in complex with UGCAUGU calculated using the entire set of NOE distance
constraints [PDB code: 2ERR] (15). Middle: overlay of the 30 final structures of Fox-1 in complex with UGCAUGU calculated using only those NOE distance
constraints that could be assigned with unlabeled RNA oligonucleotides. The structures are superimposed on the heavy atoms of the RNA; the protein backbone
is shown in black, the heavy atoms of the RNA are in red, and the side chains of F126 and K156 are in green and blue, respectively. Right: sections of one
representative structure of the Fox-1-UGACUGU complex calculated using the entire set of NOEs. The protein backbone is depicted in ribbon representation
(gray), aromatic protein side chains are shown in black, and the RNA is shown in red. Protons are displayed in gray.
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introduction of these 13C-labeled nucleotides into RNA
sequences permitted a straightforward and unambiguous res-
onance assignment of their complexes with PTB and Fox-1.
The analysis of sets of RNA sequences with alternating
labeling patterns allowed the assignments of numerous
unusual sugar–sugar and intermolecular NOEs, which sub-
stantially improved the precision and accuracy of the result-
ing structures. Use of chemically synthesized 13C-labeled
RNA sequences is likely to facilitate the study of single-
stranded RNA binding proteins in complex with their target
RNAs (21), particularly RNA binding proteins targeting
low complexity or repeat sequences that are numerous in
posttranscriptional gene regulation (22–24).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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